Q1 FY26: Revenue Growth Accelerates 60% Year on Year
Creo Medical has kicked off 2026 with a punchy start. Management reports c.60% year-on-year revenue growth for Q1 FY26, which lands at the very top end of expectations. That’s a strong continuation of the momentum they highlighted for FY25 and sets a constructive tone for the year.
Importantly, the company says this performance supports its view that full-year 2026 revenue growth will land between 40% and 60%. In other words, a hot first quarter hasn’t tempted them to over-promise, but it has strengthened confidence in the existing growth range.
What the RNS Actually Says (and What It Doesn’t)
The update is simple and focused: revenue up c.60% versus Q1 FY25, operational efficiency remains a priority, and the manufacturing sale-and-outsourcing plan is expected to cut underlying operating costs by 15% on an annualised basis compared with FY25. Commercial progress is said to be supported by “excellent clinical validation.”
Worth noting what’s not disclosed: no absolute revenue numbers for Q1, no cash balance, no gross margin or profitability detail, and no product or regional split. Those details should come with FY25 full-year results, expected in May 2026.
Manufacturing Sale and Outsourcing: 15% Cost Savings Targeted
On 16 April 2026, Creo announced the sale and outsourcing of its manufacturing operations. Today’s update ties a number to that move: underlying operating costs are expected to be 15% lower than FY25 on an annualised basis. “Underlying operating costs” typically refers to the running costs of the business excluding one-offs, and “annualised” means the saving once the changes have run for a full year.
Why it matters: outsourcing can free up capital and sharpen focus on commercial execution, but it also introduces execution risk during transition. Investors will want to see a clean handover, stable product supply, and confirmation of when those savings start to drop through the P&L.
Why 60% Q1 Growth Matters for 2026 Guidance
Clocking c.60% growth in Q1 – right at the ceiling of management’s expectations – is a useful early indicator for the full year. It suggests demand is landing, commercial rollout is progressing, and the product portfolio is gaining traction. In short, Q1 strength helps to de-risk the lower end of the 40%-60% guidance range.
However, a strong first quarter doesn’t automatically guarantee a straight line through the rest of the year. The range remains wide, which is sensible. We still need clarity on absolute revenue scale, seasonality, and the timing of cost saves to gauge the full-year shape.
Clinical Validation and the Product Story
Creo positions itself in minimally invasive electrosurgery, bringing advanced energy to endoscopy. The platform – CROMA powered by Kamaptive – integrates multiple energy modalities and adapts to tissue in real time for cutting, coagulation, dissection, and ablation. In practical terms, that’s about giving clinicians more control and precision through a single system.
The RNS calls out “excellent clinical validation” as a commercial driver. That’s positive for adoption, reimbursement conversations, and surgeon confidence. We don’t get study data or procedure volumes here, but the messaging is that clinical evidence is helping the sales story.
Key Numbers and Milestones
| Metric | Figure | Notes |
|---|---|---|
| Q1 FY26 revenue growth (YoY) | c.60% | Upper limit of management’s expectations |
| FY26 full-year revenue growth view | 40% – 60% | Management says Q1 underpins this range |
| Underlying operating cost reduction | 15% | Versus FY25, on an annualised basis |
| Manufacturing sale and outsourcing | Announced 16 April 2026 | Linked to the 15% cost reduction |
| FY25 results timing | May 2026 | Expected publication |
What to Watch Next in the May Results
- Absolute revenue levels and growth split – Q1 gave a rate, not a base. Numbers help size the opportunity.
- Gross margin and operating loss trajectory – to see how growth and cost savings interact.
- Timing and phasing of the 15% cost reduction – when do savings start to show in reported results.
- Any colour on sales mix across devices and geographies – useful for forecasting and margin outlook.
- Cash position and runway – not disclosed here, but crucial for execution and optionality.
My Take: Momentum + Efficiency Is the Right Combo
This is a clean, upbeat trading update. Hitting c.60% growth in Q1 at the top of expectations, then locking in a 15% operating cost reduction through outsourcing, is the kind of growth-plus-efficiency blend investors want to see from a scaling medtech.
On the flip side, the market will need the May numbers to fully calibrate valuation. We don’t have absolute revenue, margin, or cash detail today. There’s also some execution risk in any manufacturing transition, so confirmation of a smooth handover will be important.
Net-net, I read this as solidly positive: commercial momentum appears intact, guidance looks sensible, and the cost base should be leaner as the year progresses. The upcoming FY25 results are now the key catalyst to fill in the blanks.
Plain-English Jargon Buster
- YoY (year-on-year): compares a period with the same period a year earlier.
- Underlying operating costs: day-to-day costs of running the business, excluding exceptional items.
- Annualised: the effect over a full 12 months once changes are fully in place.
- Outsourcing manufacturing: a third party makes the products instead of in-house, typically to cut costs and increase flexibility.
- Clinical validation: medical evidence and real-world use that supports safety, efficacy, and adoption.
Bottom Line for Retail Investors
- Growth is running hot at c.60% YoY for Q1, underpinning a 40%-60% full-year view.
- Cost base is set to slim by 15% on an annualised basis after the manufacturing outsourcing move.
- Details on revenue scale, margins, and cash are not disclosed today – watch the May results.
- Execution during the manufacturing transition is the main operational watch-out.
Overall, a confident start to 2026 that tightens the story: faster growth and a leaner model. Let’s see the hard numbers next month.
